The Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors (PragmaTIL) is a project that received funding from the European Union’s Horizon Europe research and innovation program under grant agreement No. 101104684 and started in 2023 with 12 partners across 6 countries.
The PragmaTIL trial aims to optimize the treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment (TIL-ACT combined with ANV419) modality in academic hospitals.
The global impact of this project will not only reach patients, clinical and translational researchers, and policymakers but may also help to achieve better acceptance of these therapies by society at large.
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.pragmatil.eu
- Keywords
- Oncology, Research, Cell Therapies.
- Competitors
- Cancer Core Europe, Vall d'Hebron Institute of Oncology (VHIO), Biocat, BioRegion of Catalonia, CCIT-DK - National Center for Cancer Immune Therapy of Denmark, Code&Genes, Danish Cancer Institute, ASPHALION, The Netherlands Cancer Institute, Ricols - Preclinical Regulatory Aff. Consultancy & Support., ANAVEON AG.
Pragmatil Questions
Pragmatil's website is http://www.pragmatil.eu
Pragmatil's LinkedIn profile is https://www.linkedin.com/company/pragmatil
Pragmatil's industry is
Biotechnology Research
Pragmatil's top competitors are
Cancer Core Europe,
Vall D'hebron Institute Of Oncology (Vhio),
Biocat, Bioregion Of Catalonia,
Ccit-Dk - National Center For Cancer Immune Therapy Of Denmark,
Code&genes,
Danish Cancer Institute,
Asphalion,
The Netherlands Cancer Institute,
Ricols - Preclinical Regulatory Aff. Consultancy & Support.,
Anaveon Ag.
Pragmatil's categories are Biotechnology Research
